Cell and Gene Therapy in 2026: Progress, Challenges, and What's Coming Next
The cell and gene therapy (CGT) space is evolving at a pace that few other areas of medicine can match. What once lived in the realm of scientific ambition is now delivering real clinical outcomes and the conversation across the global biologics community has shifted decisively from “can this work?” to “how do we scale this and get it to more patients?” That is a significant transition, and one that carries enormous implications for sponsors, researchers, regulators, and the CROs supporting them.
Here is our perspective on where the field stands today, what technologies are defining the next chapter, and the challenges that still need to be solved.
The Promise of Cell and Gene Therapy Is No Longer Theoretical
Cell and gene therapies have moved well past the experimental stage. Today, we are looking at an active pipeline of hundreds of clinical-stage CGT programs globally, with approvals already in place for conditions that were considered untreatable just a decade ago , certain blood cancers, inherited blindness, spinal muscular atrophy, and rare genetic disorders. The science is working.
What makes this moment particularly exciting is the breadth of therapeutic areas now being explored.
Expanding Beyond Rare Diseases
CGT is no longer limited to ultra-rare monogenic diseases. Oncology, autoimmune conditions, cardiovascular disease, and even neurodegenerative disorders are all active areas of CGT research. The addressable patient population is expanding and so is the urgency to make these therapies accessible at scale.
CAR T-Cell Therapy: Power, Precision, and the Next Frontier
CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) remains one of the most clinically impactful innovations in modern medicine. The outcomes in certain hematologic malignancies have been remarkable. Patients with relapsed or refractory cancers are achieving durable remissions even after conventional therapies have failed. That is not incremental progress. That is transformative.
But the current generation of autologous CAR T therapies where a patient’s own T-cells are extracted, engineered, and reinfused comes with real-world complexity.
Why Manufacturing Remains a Major Challenge
The manufacturing process is highly individualized and time-intensive. Vein-to-vein time can stretch to several weeks, which in critically ill patients is a window that is not always available. And the cost structure of autologous manufacturing remains a significant barrier to broader access.
The next wave of innovation is squarely focused on addressing these limitations. “Allogeneic (off-the-shelf) CAR T therapies”, derived from healthy donor cells and pre-manufactured at scale, represent a potential step-change in accessibility and turnaround time.
The Rise of Off-the-Shelf CAR-T Therapies
Alongside this, researchers are advancing more sophisticated CAR construct designs dual-targeting CARs, armored CARs, and logic-gated CARs, that improve tumor specificity while reducing the risk of off-tumor toxicity.
For CROs operating in this space, this evolution demands increasingly robust analytical capabilities: T-cell characterization, potency assays, long-term stability testing, and comparability studies that can support both autologous and allogeneic product programs.
CRISPR and Gene Editing: From Headlines to Clinical Reality
If CAR T represents the clinical power of cell therapy, CRISPR-based (Clustered Regularly Interspaced Short Palindromic Repeats) approaches represent the precision frontier of gene editing in Cell and Gene Therapy. The approval of the first CRISPR therapy for sickle cell disease and transfusion-dependent beta-thalassemia was a landmark, a proof of concept that targeted genomic correction can work safely in humans.
But the Cell and Gene Therapy field is moving quickly beyond that first proof point. Next-generation base editing and prime editing approaches reduce the risk of unintended double-strand DNA breaks, improving the safety profile of gene editing interventions. Advances in delivery mechanisms including lipid nanoparticles, engineered viral vectors, and exosome-based platforms are expanding the range of tissues and cell types that can be targeted. In vivo editing strategies, which allow gene editing machinery to be delivered directly into the body without the need for ex vivo cell manipulation, represent a potentially transformative simplification of the treatment paradigm.
What is becoming increasingly clear across the Cell and Gene Therapy landscape is that long-term safety data and genotoxicity risk assessment are non-negotiable priorities. Regulatory agencies are asking harder, more detailed questions about off-target edits, and sponsors need research partners who can design studies that proactively address these concerns and build data packages that hold up across multiple global regulatory jurisdictions.
The Barriers to Wider Adoption and How to Overcome Them
The science is exciting. The clinical results are compelling. But broader adoption of CGT faces real, structural challenges that the industry must address together.
Manufacturing scalability remains one of the most persistent bottlenecks. CGT manufacturing is complex, process-dependent, and highly sensitive to variability. Scaling from clinical batches to commercial supply requires significant infrastructure investment, rigorous process development, and quality systems built specifically for the unique demands of living cell products and viral vector manufacturing.
Cost and patient access are equally urgent. Many approved CGT products carry price tags in the hundreds of thousands or even millions of dollars per treatment. While the one-time curative potential can be justified from a long-term health economics perspective, the reality for most patients globally is inaccessibility. Outcomes-based reimbursement models, innovative pricing agreements, and investment in decentralized manufacturing particularly in emerging markets like India, are all part of the conversation about how to change this.
Regulatory fragmentation adds another layer of complexity. CGT programs targeting global markets must navigate divergent requirements and timelines across agencies. The FDA typically takes 6–12 months for IND review of CGT products, with Breakthrough Therapy or RMAT designation potentially accelerating this. The EMA’s Committee for Advanced Therapies (CAT) adds a parallel scientific review layer that can extend timelines by several months. In India, the CDSCO guided by the New Drugs and Clinical Trials Rules 2019 and the biologics-specific guidelines has made notable strides, but approval timelines for CGT studies can still range from 6–18 months depending on product complexity. Building a cohesive regulatory strategy from the earliest stages of development, and working with CRO partners who have cross-jurisdictional experience across FDA, EMA, and CDSCO, is essential not optional.
The CRO Role in Advancing Cell and Gene Therapy
None of these challenges have simple solutions, but all of them benefit from the right partnerships. CROs with deep Cell and Gene Therapy (CGT) expertise bring more than operational capacity to a program. They bring scientific understanding of the modality, regulatory knowledge across markets, specialized analytical and manufacturing support capabilities, and the clinical experience to navigate the complexity of rare disease and oncology trials.
At Abiogenesis, we are committed to advancing the Cell and Gene Therapy and biologics space. We see our role as more than executing protocols. We are strategic partners helping CGT sponsors think through development plans, anticipate regulatory questions, and build programs designed for success from day one.
Conclusion
Cell and gene therapy is at an inflection point. The science is advancing faster than many predicted. The clinical evidence base is growing stronger. The regulatory frameworks, while still evolving, are maturing. And the patient communities who stand to benefit from these therapies are growing louder in their advocacy for faster, wider access.
The work ahead solving manufacturing scalability, reducing cost, harmonizing regulatory pathways, and designing smarter clinical trials is hard. But it is the most important work happening in biopharmaceutical development today. And it is work that no sponsor should have to navigate alone.
If your CGT program is at any stage of development and you are looking for a research partner who understands the science, the challenges, and the path forward we would welcome the conversation.
Abiogenesis Clinpharm is a full-service clinical research organization specializing in biologics and advanced therapy development. We are proud to share that Abiogenesis Clinpharm has now entered into CGT clinical trials marking a significant milestone in our journey to support next-generation therapies. Connect with us for your current or upcoming CGT studies at www.abiogenesisclinpharm.com or write to us at [email protected].